Viridian Therapeutics

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

Signal Genetics, Inc. is a commercial-stage molecular diagnostics company that specializes in providing innovative diagnostic services aimed at enhancing the decision-making process for physicians treating cancer patients. Established in April 2010, the company became the exclusive licensee of pioneering research on multiple myeloma conducted at the University of Arkansas for Medical Sciences (UAMS). This extensive research, encompassing over 30 years and involving nearly 10,000 patients, led to the creation of Signal Genetics' primary offering, MyPRS® (Myeloma Prognostic Risk Signature). This diagnostic tool assists in assessing the prognosis of multiple myeloma patients, thereby facilitating more informed treatment decisions.